OncoCyte Corp (OCX)
2.44
-0.02
(-0.81%)
USD |
NASDAQ |
Apr 25, 16:00
2.40
-0.04
(-1.64%)
Pre-Market: 20:00
OncoCyte Research and Development Expense (Quarterly): 2.547M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.547M |
| September 30, 2023 | 2.185M |
| June 30, 2023 | 2.435M |
| March 31, 2023 | 2.127M |
| December 31, 2022 | 1.378M |
| September 30, 2022 | 1.472M |
| June 30, 2022 | 2.444M |
| March 31, 2022 | 2.007M |
| December 31, 2021 | -4.005M |
| September 30, 2021 | 3.142M |
| June 30, 2021 | 2.537M |
| March 31, 2021 | 3.361M |
| December 31, 2020 | 1.80M |
| September 30, 2020 | 2.615M |
| June 30, 2020 | 3.225M |
| March 31, 2020 | 2.159M |
| December 31, 2019 | 2.318M |
| September 30, 2019 | 1.625M |
| June 30, 2019 | 1.508M |
| Date | Value |
|---|---|
| March 31, 2019 | 1.343M |
| December 31, 2018 | 1.204M |
| September 30, 2018 | 1.527M |
| June 30, 2018 | 2.322M |
| March 31, 2018 | 1.461M |
| December 31, 2017 | 1.507M |
| September 30, 2017 | 1.836M |
| June 30, 2017 | 1.997M |
| March 31, 2017 | 1.834M |
| December 31, 2016 | 1.431M |
| September 30, 2016 | 1.363M |
| June 30, 2016 | 1.195M |
| March 31, 2016 | 1.689M |
| December 31, 2015 | 1.429M |
| September 30, 2015 | 1.094M |
| June 30, 2015 | 0.886M |
| March 31, 2015 | 1.117M |
| December 31, 2014 | 1.125M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-4.005M
Minimum
Dec 2021
3.361M
Maximum
Mar 2021
1.941M
Average
2.185M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Fonar Corp | 0.416M |
| XWELL Inc | -- |
| ProPhase Labs Inc | 0.274M |
| Applied DNA Sciences Inc | 0.9358M |
| Veracyte Inc | 18.67M |